Effects of Endotoxin in Normal Human Volunteers
NCT00001303 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 198
Last updated 2018-07-05
Summary
Bacterial infections can progress to a life-threatening illness called septic shock, characterized by low blood pressure and vital organ damage. The syndrome is thought to be caused by parts of the bacteria and by the body s own immune response to the infection. A major bacterial product that interacts with the immune defenses is called endotoxin. This study will examine the body s response to endotoxin in the lungs or bloodstream. When endotoxin is given in small amounts to humans, even though it is not an infection, it triggers a set of responses that are typical of what one would see with a true bacterial infection. This allows us to study the earliest changes in molecules and cells that are involved in some bacterial infections. This type of model is safe and has been used in humans for many years to understand the body s responses during infections.
Normal volunteers 18 to 45 years of age may be eligible for this study. Candidates will have a history and physical examination, blood and urine tests, electrocardiogram (EKG) and chest X-ray. In addition, volunteers 40 to 45 years old will have an exercise stress test to screen for asymptomatic coronary artery disease. Participants will undergo one or more of the following procedures:
Bronchoscopy, Bronchoalveolar Lavage, Bronchial Brushings, and Endobronchial Mucosal Biopsies: These techniques for examining lung function are used routinely in patient care and clinical research. The mouth and nasal and lung airways are numbed with an anesthetic. A bronchoscope (pencil-thin flexible tube) is then passed through the nose into the large airways of the lung. Cells and secretions from the airways are rinsed with salt water (bronchoalveolar lavage) and a flexible brush the size of a pencil tip is passed through the bronchoscope to scrape cells lining the airways. Lastly, pieces of tissue (the size of the ball of a ballpoint pen) lining the airways are removed for examination under the microscope.
Intravenous Endotoxin: A small dose of endotoxin is injected into a vein. Blood samples are drawn at regular intervals for 8 hours after the injection and again after 1, 2, 3, 7 and 14 days to analyze the body s immune response to the bacteria in the blood.
Instilled Endotoxin in the Lungs: A small amount (2 teaspoons) of salt water is squirted through a bronchoscope into a lobe of one lung, and then salt water containing a small dose of endotoxin is squirted into the other lung. Bronchial lavage, brushing, and biopsy (see above) are then done to study the response of the lung to the endotoxin. In addition, air is withdrawn through the bronchoscope to study air components from the lung that was instilled with salt water or endotoxin.
Nitric Oxide Therapy: Endotoxin is instilled in a lung (see above) and then nitric oxide a colorless, odorless, tasteless gas mixed with room air in a concentration of 40 parts per million, is given through a cushioned mask placed over the mouth and nose. (Some participants will be given the nitric oxide mixture and others will breathe only room air through the mask to test the effects of the nitric oxide on the lung inflammation.) The mask will be worn continuously for 6 hours and removed before repeat bronchoscopy with lavage, brushing and biopsy.
Some of the above procedures require placement of a catheter (thin plastic tube) in a wrist artery to monitor blood pressure from heartbeat to heartbeat and to collect blood samples. First, the skin is numbed with an anesthetic (lidocaine). A needle is then inserted into the artery, the catheter is slipped over the needle into the vessel, and the needle is removed.
Conditions
- Healthy
- Lung Disease
- Sepsis
- Septic Shock
Interventions
- DRUG
-
Reference Endotoxin
- DRUG
-
Inhaled Nitric Oxide
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Principal Investigators
-
Anthony F Suffredini, M.D. · National Institutes of Health Clinical Center (CC)
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1992-04-06
- Primary Completion
- 2007-03-21
- Completion
- 2018-05-17
Countries
- United States
Study Locations
More Related Trials
-
Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
NCT06426407 ·Status: TERMINATED
-
Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock
NCT03974386 ·Status: COMPLETED ·Phase: NA
-
Protocol-driven Hemodynamic Support for Patients With Septic Shock
NCT00335907 ·Status: UNKNOWN ·Phase: NA
-
Citrulline in Severe Sepsis
NCT01474863 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of Molecular and Protein Biomarkers in Sepsis
NCT04289506 ·Status: UNKNOWN
-
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
NCT01310790 ·Status: COMPLETED ·Phase: PHASE4
-
Cytokine Adsorption in Severe, Refractory Septic Shock
NCT04910893 ·Status: COMPLETED ·Phase: NA
-
The Effect of Increasing the Mean Arterial Pressure on the Microcirculation and the Prognosis of Patients With Septic Shock
NCT04136080 ·Status: UNKNOWN ·Phase: NA
-
Cortisol Control of Human Inflammatory Responses to Endotoxin
NCT00396344 ·Status: COMPLETED ·Phase: NA
-
Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock
NCT03014063 ·Status: COMPLETED
-
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
NCT07203833 ·Status: RECRUITING ·Phase: NA
-
Investigate the Activity of Endotoxin in Severe Sepsis
NCT01957254 ·Status: TERMINATED
-
Preemptive Resuscitation for Eradication of Septic Shock
NCT01449721 ·Status: COMPLETED ·Phase: NA
-
Immunomodulatory Properties of Ketamine in Sepsis
NCT01089361 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
NCT05824767 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
NCT01046669 ·Status: COMPLETED ·Phase: NA
-
Early Angiotensin II in the Emergency Department
NCT06693726 ·Status: RECRUITING ·Phase: PHASE4
-
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
NCT03992378 ·Status: RECRUITING ·Phase: NA
-
Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
NCT02739373 ·Status: COMPLETED ·Phase: PHASE1
-
Angiotensin II vs. Vasopressin in Septic Shock
NCT05193370 ·Status: WITHDRAWN ·Phase: PHASE4
-
Lactate Metabolism After an Endotoxin Challenge in Healthy Humans
NCT01647997 ·Status: COMPLETED ·Phase: NA
-
Endothelium in Severe Sepsis
NCT00793442 ·Status: COMPLETED
-
Vaccine Response in Patient With Sepsis
NCT04823039 ·Status: COMPLETED ·Phase: NA
-
Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs
NCT05826223 ·Status: COMPLETED
-
Methylene Blue in Early Septic Shock
NCT04446871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3